Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

(2020) Barbara Pistilli et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

(2019) Olivier Mir et al.   CLINICAL CANCER RESEARCH

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

(2019) Stefanie L. Groenland et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use

(2019) Paul Gougis et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

(2018) Gregory P. Kalemkerian et al.   JOURNAL OF CLINICAL ONCOLOGY

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients

(2018) Rafael Reis et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

(2017) C. Hiemke et al.   PHARMACOPSYCHIATRY

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

(2014) Huixin Yu et al.   CLINICAL PHARMACOKINETICS

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies

(2014) Nicolas Widmer et al.   EUROPEAN JOURNAL OF CANCER

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

(2014) Roelof W F van Leeuwen et al.   LANCET ONCOLOGY

Sorafenib in Thyroid Cancer Patients: Learning From Toxicity

(2014) O. Huillard et al.   ONCOLOGIST

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

(2013) Nienke A. G. Lankheet et al.   THERAPEUTIC DRUG MONITORING

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

(2011) Jennifer Arrondeau et al.   INVESTIGATIONAL NEW DRUGS

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times

(2009) Yanfeng Wang et al.   THERAPEUTIC DRUG MONITORING